ArticleBlood2018
Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis.Blood advances · 2026Pooled it
- Antiphospholipid syndrome: epidemiology and outcomes in the evolving criteria era.Nature reviews. Rheumatology · 2026Review
- Antiphospholipid antibodies and cardiovascular thrombosis.Nature reviews. Cardiology · 2026Review
- IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.Frontiers in immunology · 2026Article
- A Digital Twin Strategy to Predict Thrombotic Recurrence in Antiphospholipid Syndrome Patients Treated with Direct Oral Anticoagulants vs. Vitamin K Antagonists Using Data from Real-World Populations.Journal of clinical medicine · 2025Article
- Clinical characteristics of patients with acute pulmonary embolism complicated with antiphospholipid syndrome: a case control study.BMC pulmonary medicine · 2025Article
- Thrombotic Antiphospholipid Syndrome: Recurrent Thromboses.Doklady. Biochemistry and biophysics · 2025Article
- The effect of anticoagulation therapy on the surgical outcomes of minimally invasive major gastrointestinal surgery.Surgical endoscopy · 2025Article
- Warfarin and heparin monitoring in antiphospholipid syndrome.Hematology. American Society of Hematology. Education Program · 2024Review
- Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial.Research and practice in thrombosis and haemostasis · 2024Article
- Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation.Thrombosis research · 2024Article
- The Vienna Prediction Model for identifying patients at low risk of recurrent venous thromboembolism: a prospective cohort study.European heart journal · 2024Article
- Positive antiphospholipid antibodies: observation or treatment?Journal of thrombosis and thrombolysis · 2023Review
- Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort.RMD open · 2023Article
- Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?European journal of rheumatology · 2023Article
- Neurovascular Manifestations of Iron-Deficient Anemia: Narrative Review and Practical Reflections through a Teaching Case.Journal of clinical medicine · 2022Article
- [Coagulation diagnostics in the clinical routine-part 2 : Monitoring of anticoagulation treatment, new-onset thrombocytopenia and thrombophilia].Innere Medizin (Heidelberg, Germany) · 2022Article
- An Update on Antiphospholipid Syndrome.Current rheumatology reports · 2022Review
- Antiphospholipid Syndrome-Related Pulmonary Embolism: Clinical Characteristics and Early Recognition.Frontiers in cardiovascular medicine · 2022Article
- The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis-A Two-Year Prospective Study.Biomedicines · 2021Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 8 institutions in 3 countries.
Funding
Abstract
It is uncertain whether antiphospholipid antibodies (APAs) increase the risk of recurrence after a first unprovoked venous thromboembolism (VTE). We tested for anticardiolipin antibodies, anti-β2 glycoprotein 1 antibodies, and lupus anticoagulant on 2 occasions ∼6 months apart in 307 patients with a first unprovoked VTE who were part of a prospective cohort study. We then determined if APAs were associated with recurrent thrombosis in the 290 patients who stopped anticoagulant therapy in response to negative D-dimer results. Compared with those without an APA, the hazard ratios for recurrent VTE were 1.8 (95% confidence interval [CI], 0.9-3.7;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.